BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7988721)

  • 21. Interaction of urokinase-type plasminogen activator with its receptor rapidly induces activation of glucose transporters.
    Anichini E; Zamperini A; Chevanne M; Caldini R; Pucci M; Fibbi G; Del Rosso M
    Biochemistry; 1997 Mar; 36(11):3076-83. PubMed ID: 9115983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor.
    Fibbi G; Caldini R; Chevanne M; Pucci M; Schiavone N; Morbidelli L; Parenti A; Granger HJ; Del Rosso M; Ziche M
    Lab Invest; 1998 Sep; 78(9):1109-19. PubMed ID: 9759655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
    Degryse B; Resnati M; Rabbani SA; Villa A; Fazioli F; Blasi F
    Blood; 1999 Jul; 94(2):649-62. PubMed ID: 10397732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
    Hollas W; Blasi F; Boyd D
    Cancer Res; 1991 Jul; 51(14):3690-5. PubMed ID: 1648443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-1beta regulates urokinase plasminogen activator (u-PA), u-PA receptor, soluble u-PA receptor, and plasminogen activator inhibitor-1 messenger ribonucleic acid expression in cultured human endometrial stromal cells.
    Chung HW; Wen Y; Ahn JJ; Moon HS; Polan ML
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1332-40. PubMed ID: 11238529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase inhibits HL-60 cell proliferation in vitro.
    Howell AL; Hunt JA; James TW; Mazar A; Henkin J; Zacharski LR
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):445-53. PubMed ID: 7841298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.
    Kobayashi H; Ohi H; Shinohara H; Sugimura M; Fujii T; Terao T; Schmitt M; Goretzki L; Chucholowski N; Jänicke F
    Br J Cancer; 1993 Mar; 67(3):537-44. PubMed ID: 8382511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
    Kobayashi H; Sugino D; She MY; Ohi H; Hirashima Y; Shinohara H; Fujie M; Shibata K; Terao T
    Eur J Biochem; 1998 May; 253(3):817-26. PubMed ID: 9654084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombin increases expression of urokinase receptor by activation of the thrombin receptor.
    Yang Z; Cohen RL; Lui GM; Lawrence DA; Shuman MA
    Invest Ophthalmol Vis Sci; 1995 Oct; 36(11):2254-61. PubMed ID: 7558719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of metastasis by inhibition of the urokinase receptor.
    Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
    Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
    Hudson MA; McReynolds LM
    J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
    Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
    Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The N-terminal domain of human urokinase receptor contains two distinct regions critical for ligand recognition.
    Pöllänen JJ
    Blood; 1993 Nov; 82(9):2719-29. PubMed ID: 8219225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
    Schlechte W; Brattain M; Boyd D
    Cancer Commun; 1990; 2(5):173-9. PubMed ID: 2164413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
    Fowler B; Mackman N; Parmer RJ; Miles LA
    Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor.
    Eefting D; de Vries MR; Grimbergen JM; Karper JC; van Bockel JH; Quax PH
    J Vasc Surg; 2010 Feb; 51(2):429-37. PubMed ID: 20036101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.